Drug Trial Radar · NCT00630747
Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase
Last checked: Nov 20, 2026Latest source record: Jun 10, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Sep 13, 2004
Primary completion
Jan 31, 2008
Study completion Jan 31, 2008
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Mar 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study TKT024EXT was a long-term, single-arm, open-label extension of Study TKT024, a one year Phase 2/Phase 3 registration study. The primary objective of this extension study was to collect long-term safety and clinical outcome data in Mucopolysaccharidosis II (MPS II), also known as Hunter Syndrome, from the Phase 2/Phase 3 Study TKT024. All patients enrolling into this study received weekly active treatment with idursulfase, the primary dosing regimen investigated in Study TKT024. Hunter Syndrome is an X-linked recessive lysosomal storage disease caused by a deficiency of iduronate-2-sulfatase, an enzyme required to catabolize glycosaminoglycans (GAGS) in cells. As a result, GAGs accumulate in the lysosomes leading to cellular engorgement, organomegaly, tissue destruction, and organ system dysfunction. Hunter Syndrome is a rare disease with an estimated incidence of 1 in 162,000 live births.
Conditions
- Hunter Syndrome
- Mucopolysaccharidosis II (MPS II)
Interventions
IdursulfaseBiological
Solution for intravenous infusion, 0.5 mg/kg once-weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105Time frame: Baseline and at Week 105
- Change From Baseline in Mean Distance Walked in the 6-minute Walk Test (6MWT) at Week 105Time frame: Baseline and at Week 105
Locations
52 sites in 10 countries. Site status is shown where the registry gives one.
St. Joseph's Hospital
Phoenix, Arizona
Pediatric Clinical Research Center, Children's Hospital Oakland
Oakland, California
The Children's Hospital
Denver, Colorado
Harbin Clinic
Rome, Georgia
Mid-Illinois Hematology and Oncology Associates
Normal, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Children's Hospital Boston
Boston, Massachusetts
Saint Louis University Cardinal Glennon Children's Hospital
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Upstate Medical University, State University of New York (SUNY)
Syracuse, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Baylor College of Medicine Texas Children's Hospital
Houston, Texas
University of Utah Hospital
Salt Lake City, Utah
Franciscan Skemp Healthcare
La Crosse, Wisconsin
Fundacao Universidade de Ciencias da Saude de Alagoas Governador Lamenha Filho / UNCISAL
Maceió, Alagoas, Brazil
Clinica Casa de Saude Sao Joao
Barreiras, Estado de Bahia, Brazil
c-HUPES/UFBA
Salvador, Estado de Bahia, Brazil
Hospital Universitario da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul
Campo Grande, Mato Grosso do Sul, Brazil
Instituto de Puericultura e Pediatria Martagao Gesteira / Hospital Pediatrico
Rio de Janeiro, Rio de Janeiro, Brazil
Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica
Porto Alegre, Rio Grande do Sul, Brazil
UNIFESP Instituto de Oncologia Pediatrica
São Paulo, São Paulo, Brazil
Instituto da Crianca / Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
São Paulo, São Paulo, Brazil
The Hospital for Sick Children Research Institute
Toronto, Ontario, Canada
University of Montreal / Hopital Ste-Justine
Montreal, Quebec, Canada
Hopital Edouard Herriot
Lyon, France
Hopital de Hautepierre
Strasbourg, France
Hospital Ducuing
Toulouse, France
Universitatsklinikum Aachen Kinderklinik
Aachen, Germany
Universitatsklinik Dusseldorf Kinderklinik
Düsseldorf, Germany
Justus-Liebig Universitat
Giessen, Germany
Universitatsklinikum Gottingen
Göttingen, Germany
Universitatsklinikum Hamburg Eppendorf
Hamburg, Germany
Children's University Hospital Mainz AG
Mainz, Germany
Universita Milano Bicocca / Ospedale S. Gerardo
Milan, Italy
Universita degli Studi di Napoli Federico II
Naples, Italy
Universita di Padova
Padova, Italy
Ospedale S. S. Annunziata
Savigliano, Italy
Spitalul Clinic de Copii
Cluj-Napoca, Cluj, Romania
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.